Therapeutics for gait blocking in patients with Parkinson's
Main Article Content
Abstract
Parkinson's disease is a chronic, progressive neurological disorder that primarily affects the motor system, including walking. Gait disturbance is one of the most disabling and debilitating symptoms for Parkinson's patients. The objective is to define Parkinson's disease interventions addressing traditional and non-traditional approaches to improve gait in patients with Parkinson's disease and provide recommendations for clinical practice. A narrative review of the literature and a systematic review of randomized controlled trials (RCTs) were carried out. These reviews summarized Parkinson's disease interventions addressing traditional and non-traditional approaches to improving gait in patients with PD over the past 10 years, all searches were conducted in PubMed and Scopus and study selection was performed independently. . The main results show that gait blockage is a debilitating and common symptom in patients with Parkinson's disease (PD), which significantly limits their mobility and quality of life. Pharmacological approaches are established, such as levodopa, and the juxtaposition of deferiprone that can temporarily improve gait in some patients, and physical therapies, such as physical therapy and deep brain stimulation, are evidenced. It is concluded that neurosurgical, pharmacological or non-pharmacological therapies can be used based on a thorough evaluation of the patient's clinical history, the severity of symptoms and the potential risks and benefits of the intervention.
Downloads
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
1. Derechos de autor
Las obras que se publican en 593 Digital Publisher CEIT están sujetas a los siguientes términos:
1.1. 593 Digital Publisher CEIT, conserva los derechos patrimoniales (copyright) de las obras publicadas, favorece y permite la reutilización de las mismas bajo la licencia Licencia Creative Commons 4.0 de Reconocimiento-NoComercial-CompartirIgual 4.0, por lo cual se pueden copiar, usar, difundir, transmitir y exponer públicamente, siempre que:
1.1.a. Se cite la autoría y fuente original de su publicación (revista, editorial, URL).
1.1.b. No se usen para fines comerciales u onerosos.
1.1.c. Se mencione la existencia y especificaciones de esta licencia de uso.
References
Allen, N. E., Canning, C. G., Almeida, L. R. S., Bloem, B. R., Keus, S. H. J., Löfgren, N., Nieuwboer, A., Verheyden, G. S. A. F., Yamato, T. P., & Sherrington, C. (2022). Interventions for preventing falls in Parkinson’s disease. Cochrane Database of Systematic Reviews, 2022(6). https://doi.org/10.1002/14651858.CD011574.pub2
Bloem, B. R., Okun, M. S., & Klein, C. (2021). Parkinson’s disease. The Lancet, 397(10291), 2284–2303. https://doi.org/10.1016/S0140-6736(21)00218-X
Church, F. C. (2021). Review treatment options for motor and non‐motor symptoms of parkinson’s disease. Biomolecules, 11(4). https://doi.org/10.3390/biom11040612
Cucca, A., Di Rocco, A., Acosta, I., Beheshti, M., Berberian, M., Bertisch, H. C., Droby, A., Ettinger, T., Hudson, T. E., Inglese, M., Jung, Y. J., Mania, D. F., Quartarone, A., Rizzo, J. R., Sharma, K., Feigin, A., Biagioni, M. C., & Ghilardi, M. F. (2021). Art therapy for Parkinson’s disease. Parkinsonism and Related Disorders, 84, 148–154. https://doi.org/10.1016/j.parkreldis.2021.01.013
Degirmenci, Y., Angelopoulou, E., Epameinondas, V., & Bougea, A. (2023). Deterioro cognitivo en la enfermedad de Parkinson: Descripción general centrándose en productos farmacéuticos emergentes. MEDICINA, 59. https://doi.org/10.3390/medicina59101756
Degirmenci, Y., Angelopoulou, E., Georgakopoulou, V. E., & Bougea, A. (2023). Cognitive Impairment in Parkinson’s Disease: An Updated Overview Focusing on Emerging Pharmaceutical Treatment Approaches. Medicina (Lithuania), 59(10), 1–17. https://doi.org/10.3390/medicina59101756
Deuschl, G., Antonini, A., Costa, J., Śmiłowska, K., Berg, D., Corvol, J. C., Fabbrini, G., Ferreira, J., Foltynie, T., Mir, P., Schrag, A., Seppi, K., Taba, P., Ruzicka, E., Selikhova, M., Henschke, N., Villanueva, G., & Moro, E. (2022). European Academy of Neurology/Movement Disorder Society - European Section guideline on the treatment of Parkinson’s disease: I. Invasive therapies. European Journal of Neurology, 29(9), 2580–2595. https://doi.org/10.1111/ene.15386
Espinoza-Vinces, C., Villino-Rodríguez, R., Atorrasagasti-Villar, A., Martí-Andrés, G., & Luquin, M.-R. (2023). Impact of Safinamide on Patient-Reported Outcomes in Parkinson’s Disease. Patient Related Outcome Measures, 14, 285–295. https://doi.org/10.2147/prom.s369590
Gaßner, H., Trutt, E., Seifferth, S., Friedrich, J., Zucker, D., Salhani, Z., Adler, W., Winkler, J., & Jost, W. H. (2022). Treadmill training and physiotherapy similarly improve dual task gait performance: a randomized-controlled trial in Parkinson’s disease. Journal of Neural Transmission, 129(9), 1189–1200. https://doi.org/10.1007/s00702-022-02514-4
Hariz, M., & Blomstedt, P. (2022a). Deep brain stimulation for Parkinson’s disease. Journal of Internal Medicine, 292(5), 764–778. https://doi.org/10.1111/joim.13541
Hariz, M., & Blomstedt, P. (2022b). Deep brain stimulation for Parkinson’s disease. Journal of Internal Medicine, 292(5), 764–778. https://doi.org/10.1111/joim.13541
Horsager, J., Andersen, K. B., Knudsen, K., Skjærbæk, C., Fedorova, T. D., Okkels, N., Schaeffer, E., Bonkat, S. K., Geday, J., Otto, M., Sommerauer, M., Danielsen, E. H., Bech, E., Kraft, J., Munk, O. L., Hansen, S. D., Pavese, N., Göder, R., Brooks, D. J., … Borghammer, P. (2020). Brain-first versus body-first Parkinson’s disease. Brain, 143(10), 3077–3088. https://doi.org/10.1093/brain/awaa238
Horsager, J., Andersen, K., Knudsen, K., Skjærbæk, C., Fedorova, T., Okkels, N., Schaeffer, E., Bonkat, S., & Otto, M. (2020). Body-first versus brain-first biological subtyping of Parkinson’s disease. Brain, 143(10), 2871–2873. https://doi.org/10.1093/brain/awaa293
Hulzinga, F., Seuthe, J., D’Cruz, N., Ginis, P., Nieuwboer, A., & Schlenstedt, C. (2023). Split-Belt Treadmill Training to Improve Gait Adaptation in Parkinson’s Disease. Movement Disorders, 38(1), 92–103. https://doi.org/10.1002/mds.29238
Johansson, M. E., Cameron, I. G. M., Van der Kolk, N. M., de Vries, N. M., Klimars, E., Toni, I., Bloem, B. R., & Helmich, R. C. (2022). Aerobic Exercise Alters Brain Function and Structure in Parkinson’s Disease: A Randomized Controlled Trial. Annals of Neurology, 91(2), 203–216. https://doi.org/10.1002/ana.26291
Krauss, J. K., Lipsman, N., Aziz, T., Boutet, A., Brown, P., Chang, J. W., Davidson, B., Grill, W. M., Hariz, M. I., Horn, A., Schulder, M., Mammis, A., Tass, P. A., Volkmann, J., & Lozano, A. M. (2021). Technology of deep brain stimulation: current status and future directions. Nature Reviews Neurology, 17(2), 75–87. https://doi.org/10.1038/s41582-020-00426-z
Li, G., Huang, P., Cui, S. S., Tan, Y. Y., He, Y. C., Shen, X., Jiang, Q. Y., Huang, P., He, G. Y., Li, B. Y., Li, Y. X., Xu, J., Wang, Z., & Chen, S. Di. (2022). Mechanisms of motor symptom improvement by long-term Tai Chi training in Parkinson’s disease patients. Translational Neurodegeneration, 11(1), 1–10. https://doi.org/10.1186/s40035-022-00280-7
Mahoney-Sánchez, L., Bouchaoui, H., Ayton, S., Devos, D., Duce, J. A., & Devedjian, J. C. (2021). Ferroptosis and its potential role in the physiopathology of Parkinson’s Disease. Progress in Neurobiology, 196, 1–52. https://doi.org/10.1016/j.pneurobio.2020.101890
Prange, S., Klinger, H., Laurencin, C., Danaila, T., & Thobois, S. (2022). Depression in Patients with Parkinson’s Disease: Current Understanding of its Neurobiology and Implications for Treatment. Drugs and Aging, 39(6), 417–439. https://doi.org/10.1007/s40266-022-00942-1
Sarasso, E., Agosta, F., Piramide, N., Gardoni, A., Canu, E., Leocadi, M., Castelnovo, V., Basaia, S., Tettamanti, A., Volontè, M. A., & Filippi, M. (2021). Action Observation and Motor Imagery Improve Dual Task in Parkinson’s Disease: A Clinical/fMRI Study. Movement Disorders, 36(11), 2569–2582. https://doi.org/10.1002/mds.28717
Sun, C., & Armstrong, M. J. (2021). Treatment of parkinson’s disease with cognitive impairment: Current approaches and future directions. Behavioral Sciences, 11(4). https://doi.org/10.3390/bs11040054
Tan, Y. Y., Jenner, P., & Chen, S. Di. (2022). Monoamine Oxidase-B Inhibitors for the Treatment of Parkinson’s Disease: Past, Present, and Future. Journal of Parkinson’s Disease, 12(2), 477–493. https://doi.org/10.3233/JPD-212976
Van Den Berge, N., & Ulusoy, A. (2022). Animal models of brain-first and body-first Parkinson’s disease. Neurobiology of Disease, 163, 105599. https://doi.org/10.1016/j.nbd.2021.105599
Vijiaratnam, N., Simuni, T., Bandmann, O., Morris, H. R., & Foltynie, T. (2021). Progress towards therapies for disease modification in Parkinson’s disease. The Lancet Neurology, 20(7), 559–572. https://doi.org/10.1016/S1474-4422(21)00061-2
Yan, J., Smith, R., & Lee, L. (2022). Congelación marcha en la enfermedad sistemática y un metanálisis en red. Revista de Neurología, 269, 3325–3327. https://doi.org/10.1007/s00415-022-11076-0